GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
111
What is the history of 111, Inc.?
Founded in 2010, 111, Inc. began with a vision to digitize China's healthcare. It aimed to make healthcare more accessible and affordable through an integrated online and offline platform.
This integrated approach connects patients, doctors, and pharmacies, tackling inefficiencies in traditional healthcare systems. The company operates an online pharmacy, consultation services, retail pharmacies, and a B2B platform.
The company's journey includes its listing on NASDAQ under the ticker YI in September 2018. As of 2025, its revenue (TTM) is $1.99 billion USD, a slight decrease from $2.00 billion USD in 2024. This reflects its significant market presence as a leading digital healthcare platform in China, offering services like 111 BCG Matrix to pharmaceutical companies.
What is the 111 Founding Story?
The 111 company history began in 2010 when Dr. Gang Yu and Mr. Junling Liu co-founded the enterprise in Shanghai, China. Their shared vision was to revolutionize China's healthcare sector by creating a comprehensive online and offline platform that digitally connected patients with essential drugs and medical services, addressing the inefficiencies and high costs prevalent in the traditional system. This initiative marked the start of the 111 company origins.
The Founding Story of 111 Company
The founding of 111 company was driven by a desire to streamline China's complex healthcare landscape. Leveraging their extensive experience from roles at Dell and Amazon, the co-founders aimed to build the nation's largest integrated healthcare platform.
- Co-founded in 2010 by Dr. Gang Yu and Mr. Junling Liu in Shanghai, China.
- Founders possessed prior experience from Dell and Amazon, focusing on technology and supply chain.
- Initial focus was on addressing inefficiencies in China's traditional healthcare supply chain.
- The vision was to create an integrated online and offline healthcare platform.
The early days of 111 company saw its establishment as an online pharmacy in 2010. While specific initial funding details are not widely publicized, the company's foundational business model revolved around direct-to-consumer sales of pharmaceutical and healthcare products. This strategic approach to market entry was informed by the founders' previous success with Yihaodian, an e-commerce venture that achieved significant scale, serving over 100 million users and generating more than RMB30 billion in annual revenue before its acquisition. This background provided invaluable insights into scaling digital platforms and optimizing customer reach, crucial elements in the Marketing Strategy of 111.
In April 2018, the company, previously known as New Peak Group, officially changed its name to 111, Inc. This rebranding marked a significant point in the 111 company timeline, reflecting its evolving identity and expanded ambitions within the healthcare sector. The historical development of 111 company is characterized by its commitment to technological innovation and its strategic positioning to address critical needs in the Chinese healthcare market.
Complete 111 Strategy Bundle
- 6 Full Frameworks, 1 Company – All Pre-Researched
- Each Framework Fully Sourced with Real Company Data
- Built for Strategy Courses, Case Studies & MBA Programs
- Adapt to Your Assignment – No Starting from Scratch
- 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's
What Drove the Early Growth of 111?
The early phase of the 111 company saw its establishment as an online pharmacy, initially known as 1 Pharmacy. A significant Series B funding round of $100 million in 2016 propelled its expansion and platform development.
Strategic Shift to 'New Retail' Model
In 2016, the company pivoted from a purely B2C model to a 'New Retail' platform. This involved integrating its online pharmacy with an offline network, utilizing smart supply chain and cloud solutions to enhance efficiency and customer experience.
Expansion of Services and B2B Reach
The company broadened its services to include online healthcare via its internet hospital, 1 Clinic, offering consultations and electronic prescriptions. The launch of 1 Drug Mall, an online wholesale pharmacy, served B2B clients, empowering a vast network of offline pharmacies.
NASDAQ IPO and Financial Milestones
A major milestone was its NASDAQ IPO on September 12, 2018, raising approximately $100 million. This marked the company as the first Internet health company from China to list on a US exchange.
Achieving Operational Profitability
The company achieved operational profitability in the first quarter of 2024, with income from operations at RMB3.7 million. This trend continued into Q1 2025, with net revenues stable at RMB3.5 billion and operating expenses reduced to 5.5% of net revenues.
From PESTLE Factors to Full Strategy Bundle
- PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
- Every Strategic Angle Covered – Nothing Left to Research
- Pre-filled with Company-Specific Research
- No Missing Sections for Your Case Study
- One Download Covers Your Entire Company Analysis
What are the key Milestones in 111 history?
The history of 111 company is marked by strategic advancements and adaptation to market dynamics. Key milestones include the development of its 'New Retail' platform and S2B2C model, designed to streamline the pharmaceutical value chain by integrating online and offline operations. The company has consistently invested in technology, leveraging AI for personalized services and operational efficiency. As of September 2024, 111 company held 28 patents, underscoring its commitment to innovation and securing its competitive edge.
| Year | Milestone |
|---|---|
| 2024 | Achieved its first-ever annual operating profit. |
| September 2024 | Held 28 patents, enhancing its competitive advantages. |
| Q1 2025 | Achieved innovative applications of AI in pharmaceutical qualification review, improving efficiency by over 100%. |
| Q1 2025 | Maintained operational profitability and positive operating cash flow. |
Innovations at 111 company have centered on leveraging technology to optimize the pharmaceutical supply chain. The company's 'New Retail' platform and S2B2C model represent a significant step in integrating online and offline channels for greater efficiency. Furthermore, the application of AI in Q1 2025 for pharmaceutical qualification review and shared inventory upgrades has demonstrably improved operational performance and order fulfillment rates.
'New Retail' Platform and S2B2C Model
This innovation integrates online and offline channels to enhance efficiency within the pharmaceutical value chain, facilitating better service for consumers through businesses.
AI-Driven Operational Systems
The company has invested in AI tools for personalized recommendations and efficient order processing, supported by a comprehensive internal digital operation system that boosts efficiency.
AI in Pharmaceutical Qualification Review
In Q1 2025, AI was applied to improve the efficiency of pharmaceutical qualification reviews by over 100%.
AI for Shared Inventory Upgrades
AI algorithms were utilized for shared inventory upgrades, transforming the supply chain into a dual-resource integration and significantly improving order fulfillment rates.
Patent Portfolio Expansion
As of September 2024, the company had expanded its patent portfolio to include 28 patents, strengthening its intellectual property and market position.
Operational Profitability
The company achieved its first-ever annual operating profit in fiscal year 2024 and maintained operational profitability in Q1 2025, demonstrating improved financial management.
Challenges faced by 111 company include macroeconomic headwinds and increased competition within China's healthcare sector, which saw retail pharmacy sector sales decline by 2.2% year-over-year in the first nine months of 2024. The company's B2C segment experienced a revenue drop of 28% year-over-year in Q1 2025, indicating difficulties in its direct-to-consumer operations. Additionally, regulatory changes and heightened oversight in the healthcare system have presented ongoing pressures.
Market Competition and Economic Headwinds
Intensifying competition and macroeconomic factors have impacted the business, with China's retail pharmacy sector experiencing a sales decrease in late 2024.
B2C Segment Revenue Decline
The company's direct-to-consumer segment saw a significant revenue decline of 28% year-over-year in Q1 2025, reflecting challenges in this area.
Regulatory Environment
Changes and increased oversight within the healthcare system, including measures against corruption, have added pressure to the company's supply chain operations.
Cost Management and Operational Discipline
In response to challenges, the company focused on operational discipline, reducing operating expenses by 4.8% in Q1 2025, including significant cuts in selling, marketing, and technology costs. This strategic focus is detailed further in the Growth Strategy of 111.
Maintaining Profitability Amidst Challenges
Despite market difficulties, the company achieved its first-ever annual operating profit in fiscal year 2024 and maintained operational profitability and positive operating cash flow in Q1 2025.
Efficiency Improvements
The company demonstrated improved operational efficiency by reducing total operating expenses by 30 basis points as a percentage of net revenues in Q1 2025.
111 Business Model + Strategy Bundle
- Ideal for Essays, Case Studies & Slides
- Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
- Company-Specific Content Already Organized
- One Bundle Replaces Days of Independent Research
- Buy the Bundle Once. Use Across All Your Assignments
What is the Timeline of Key Events for 111?
The journey of 111, Inc. began in 2010 as an online pharmacy in Shanghai, co-founded by Gang Yu and Junling Liu. The company experienced significant growth, securing $100 million in Series B funding in 2016 and transitioning to a 'New Retail' platform. A pivotal moment was its IPO on NASDAQ in September 2018, raising approximately $100 million. The company's strategic direction evolved towards digitalizing pharmacies and expanding cloud-based solutions. Notably, 111, Inc. achieved its first quarterly operational profitability in Q1 2024 and followed this with a second consecutive profitable quarter in Q2 2024. The fiscal year ending March 20, 2025, marked a significant milestone with the company reporting its first-ever annual operating profit of RMB2.1 million (US$0.3 million) and positive operating cash flow of RMB263.0 million (US$36.0 million), with total net revenues reaching RMB14.4 billion (US$2.0 billion). The company also regained Nasdaq compliance in February 2025.
| Year | Key Event |
|---|---|
| 2010 | Co-founded as an online pharmacy in Shanghai by Gang Yu and Junling Liu. |
| 2016 | Secured $100 million in Series B funding and began transforming into a 'New Retail' platform. |
| 2018 | Changed its name to 111, Inc. and completed its IPO on NASDAQ. |
| 2019-2020 | Shifted focus to digitalization of pharmacies and expansion of cloud-based solutions. |
| Q1 2024 | Achieved first-ever quarterly operational profitability. |
| Q2 2024 | Reported operational profitability for the second consecutive quarter. |
| FY 2024 (ending March 20, 2025) | Achieved first-ever annual operating profit and positive operating cash flow. |
| February 2025 | Regained Nasdaq compliance. |
| Q1 2025 (ending June 19, 2025) | Maintained operational profitability and positive operating cash flow. |
Expanding Fulfillment Network
The company plans to significantly expand its reach by adding at least 14 more fulfillment centers in 2025. This expansion is crucial for increasing coverage and serving a broader customer base.
AI and Digital Innovation
Continued investment in AI and digital applications is a core strategy. These advancements aim to boost operational efficiency, particularly in areas like pharmaceutical qualification review and optimizing shared inventory.
Growth Drivers Identified
Management is confident in long-term growth, driven by the ongoing digitalization of healthcare. Key factors include the shift of pharmaceutical sales towards retail pharmacies and the increasing healthcare demands of China's aging population.
Long-Term Market Potential
While short-term stock performance may see fluctuations, long-term forecasts for 2030 and beyond suggest significant potential returns. The company's vision is to build a comprehensive healthcare ecosystem in China through technological innovation.
From Five Forces to Full Company Analysis
- Includes SWOT, PESTLE, BMC, BCG and 4P's
- Pre-Researched with Company-Specific Data
- Best Value for a Complete Analysis
- Ready to Adapt for Your Case Study
- Ready for Essays and Slidesd
- What is Competitive Landscape of 111 Company?
- What is Growth Strategy and Future Prospects of 111 Company?
- How Does 111 Company Work?
- What is Sales and Marketing Strategy of 111 Company?
- What are Mission Vision & Core Values of 111 Company?
- Who Owns 111 Company?
- What is Customer Demographics and Target Market of 111 Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.